[(99m)Tc]Tilmanocept Accurately Detects Sentinel Lymph Nodes and Predicts Node Pathology Status in Patients with Oral Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Multi-institutional Trial

BACKGROUND: [(99m)Tc]Tilmanocept, a novel CD206 receptor-targeted radiopharmaceutical, was evaluated in an open-label, phase III trial to determine the false negative rate (FNR) of sentinel lymph node biopsy (SLNB) relative to the pathologic nodal status in patients with intraoral or cutaneous head...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Ann Surg Oncol
Autores principales: Agrawal, Amit, Civantos, Francisco J., Brumund, Kevin T., Chepeha, Douglas B., Hall, Nathan C., Carroll, William R., Smith, Russell B., Zitsch, Robert P., Lee, Walter T., Shnayder, Yelizaveta, Cognetti, David M., Pitman, Karen T., King, Dennis W., Christman, Lori A., Lai, Stephen Y.
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer US 2015
Materias:
Head and Neck Oncology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4565859/
https://ncbi.nlm.nih.gov/pubmed/25670018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-015-4382-x
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares